Stiripentol for the treatment of primary hyperoxaluria and calcium oxalate nephropathy.
Publication
, Journal Article
Wyatt, CM; Drüeke, TB
Published in: Kidney Int
January 2020
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Kidney Int
DOI
EISSN
1523-1755
Publication Date
January 2020
Volume
97
Issue
1
Start / End Page
17 / 19
Location
United States
Related Subject Headings
- Urology & Nephrology
- Nephrolithiasis
- Hyperoxaluria, Primary
- Hyperoxaluria
- Humans
- Ethylene Glycols
- Dioxolanes
- Calcium Oxalate
- Calcium
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Wyatt, C. M., & Drüeke, T. B. (2020). Stiripentol for the treatment of primary hyperoxaluria and calcium oxalate nephropathy. Kidney Int, 97(1), 17–19. https://doi.org/10.1016/j.kint.2019.06.011
Wyatt, Christina M., and Tilman B. Drüeke. “Stiripentol for the treatment of primary hyperoxaluria and calcium oxalate nephropathy.” Kidney Int 97, no. 1 (January 2020): 17–19. https://doi.org/10.1016/j.kint.2019.06.011.
Wyatt CM, Drüeke TB. Stiripentol for the treatment of primary hyperoxaluria and calcium oxalate nephropathy. Kidney Int. 2020 Jan;97(1):17–9.
Wyatt, Christina M., and Tilman B. Drüeke. “Stiripentol for the treatment of primary hyperoxaluria and calcium oxalate nephropathy.” Kidney Int, vol. 97, no. 1, Jan. 2020, pp. 17–19. Pubmed, doi:10.1016/j.kint.2019.06.011.
Wyatt CM, Drüeke TB. Stiripentol for the treatment of primary hyperoxaluria and calcium oxalate nephropathy. Kidney Int. 2020 Jan;97(1):17–19.
Published In
Kidney Int
DOI
EISSN
1523-1755
Publication Date
January 2020
Volume
97
Issue
1
Start / End Page
17 / 19
Location
United States
Related Subject Headings
- Urology & Nephrology
- Nephrolithiasis
- Hyperoxaluria, Primary
- Hyperoxaluria
- Humans
- Ethylene Glycols
- Dioxolanes
- Calcium Oxalate
- Calcium
- 3202 Clinical sciences